{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T17:43:08Z","timestamp":1781890988216,"version":"3.54.5"},"reference-count":9,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hemodialysis International"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>The suggested dose of ceftazidime\u2010avibactam (CEF\/AVI) in patient with multidrug resistant organisms and utilizing renal replacement therapies (RRTs) is not validated in clinical studies. The objective of this study was to evaluate the microbiologic cure of bacteremia and pneumonia using the recommended CEF\/AVI dosing in patients utilizing RRT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective observational study conducted at our institution between September 15, 2018 and March 15, 2022. The primary end point was to determine the microbiologic cure. The secondary end points were the clinical cure, 30\u2010day recurrence, 30\u2010day all cause mortality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fifty\u2010six patients met the inclusion criteria, 36 (64.3%) were males, the median age was 69 (59.5\u201379.3) years, and the median weight was 69 (60\u201383.8)\u2009kg. Pneumonia represented 34 (60.7%) of infections. Microbiologic cure was achieved in 32 (57%) subjects. However, clinical cure was achieved in 23 (71.9%) patients in the microbiologic cure group versus 12 (50%) in the microbiologic failure group (<jats:italic>p<\/jats:italic>\u2009=\u20090.094). The 30\u2010day recurrence occurred in 2 (6.3%) patients in the microbiologic cure group versus 3 (12.5%) in the microbiologic failure group (<jats:italic>p<\/jats:italic>\u2009=\u20090.673). Further, the 30\u2010day all\u2010cause mortality was 18 (56.3%) versus 10 (41.7%) in both groups respectively (<jats:italic>p<\/jats:italic>\u2009=\u20090.28). The most used dose in patients utilizing continuous veno\u2010venous hemofiltration (CVVH) was 1.25\u2009g q8h, while the dose was 1.25\u2009g q24h in those who utilized intermittent hemodialysis (IHD). The multivariate logistic regression indicated that bacteremia (OR 41.5 [3.77\u201346]), <jats:italic>Enterobacterales<\/jats:italic> (OR 5.4 [1.04\u201327.9]), and the drug daily dose (OR 2.33 [1.15\u20134.72]) were independently associated with microbiologic cure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Microbiologic cure of ceftazidime\u2010avibactam in patient utilizing CVVH and IHD is dependent on bacteremia diagnosis, the drug daily dose, and bacterial species. These findings need to be replicated in a larger prospective study, with no recommendations in those utilizing RRT.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hdi.13090","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T11:41:12Z","timestamp":1683286872000},"page":"289-295","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Microbiologic outcomes of ceftazidime\u2010avibactam dosing in patients with sepsis utilizing renal replacement therapies"],"prefix":"10.1111","volume":"27","author":[{"given":"Wasim S.","family":"El Nekidy","sequence":"first","affiliation":[{"name":"Department of Pharmacy Cleveland Clinic Abu Dhabi  Abu Dhabi UAE"},{"name":"Department of Medicine Cleveland Clinic Lerner College of Medicine of Case Western Reserve University  Cleveland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mooza","family":"Al Ali","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Cleveland Clinic Abu Dhabi  Abu Dhabi UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emna","family":"Abidi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Cleveland Clinic Abu Dhabi  Abu Dhabi UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Islam M.","family":"Ghazi","sequence":"additional","affiliation":[{"name":"Arnold and Marie Schwartz College of Pharmacy Long Island University  Brookville New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar","family":"Attallah","sequence":"additional","affiliation":[{"name":"Department of Nephrology Nephrology Associates of Kentuckiana  Louisville Kentucky USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania","family":"El Lababidi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Cleveland Clinic Abu Dhabi  Abu Dhabi UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mooty","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Cleveland Clinic Abu Dhabi  Abu Dhabi UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Ghosn","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Cleveland Clinic Abu Dhabi  Abu Dhabi UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihad","family":"Mallat","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Cleveland Clinic Abu Dhabi  Abu Dhabi UAE"},{"name":"Department of Medicine Cleveland Clinic Lerner College of Medicine of Case Western Reserve University  Cleveland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,5,5]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9020071"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00464-17"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa061"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11050546"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.793"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/hdi.12377"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02497-17"},{"key":"e_1_2_8_9_1","unstructured":"Food and Drug Administration. Highlights of prescribing information. Ceftazidime\u2010avibactam package insert 2015. AVYCAZ safely and effectively. Allergen (fda.gov)."},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-06050-1"}],"container-title":["Hemodialysis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hdi.13090","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:50:25Z","timestamp":1692319825000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hdi.13090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,5]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1111\/hdi.13090"],"URL":"https:\/\/doi.org\/10.1111\/hdi.13090","archive":["Portico"],"relation":{},"ISSN":["1492-7535","1542-4758"],"issn-type":[{"value":"1492-7535","type":"print"},{"value":"1542-4758","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,5]]},"assertion":[{"value":"2023-02-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}